KLH
KLH is a biological therapy with 8 clinical trials. Historical success rate of 87.5%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
2
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
87.5%
7 of 8 finished
12.5%
1 ended early
0
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Clinical Trials (8)
Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)
S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome
All 8 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 8